Lantheus Holdings (LNTH, Medical supplies) Stock Valuation & Fair Value
Mixed on our testsPending takeover · $102.50 cashLantheus Holdings (LNTH, Medical supplies) trades at a current P/E of 18.3, about 19% above its historical normal valuation, with a forward growth estimate of 15.8% and a PEG of 1.16. Analysts' one-year estimates have been hit 20% of the time. Priced at its historical normal P/E of 15.4 on the same blended earnings, the 2026-11-06 close of $100.61 corresponds to about $84.50 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $100.61 at the Nov 6 close, 0.4% above the 20-day average ($100.24) and 0.3% above the 50-day ($100.27).
- RSI (14) at 55.3.
- 52-week range $50.69 to $110.94: the price is 9.3% below the high and 98.5% above the low.
The Street vs SeerForecast
Wall Street's mean price target for LNTH is $106.99 across 8 analysts, 6.3% above the current price. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- Pending takeover: Curium agreed to pay $102.50 a share in cash plus a contingent value right worth up to $12.00
Verdict history
tickerseer's rating has been mixed on our tests since 2026-07-31.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, and the cheapest and dearest.
Show all 29 readings
Frequently asked questions
Is Lantheus Holdings stock overvalued?
At a current P/E of 18.3 versus its historical normal P/E of 15.4, Lantheus Holdings trades about 19% above its typical valuation, with a PEG of 1.16 on 15.8% forward growth. tickerseer currently rates it mixed on our tests.
What is Lantheus Holdings's fair value and PEG?
Lantheus Holdings trades at a current P/E of 18.3 against a historical normal P/E of 15.4, a PEG of 1.16, and a forward growth estimate of 15.8%. Priced at its historical normal P/E of 15.4 on the same blended earnings, the 2026-11-06 close of $100.61 corresponds to about $84.50 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Lantheus Holdings changed?
tickerseer's rating has been mixed on our tests since 2026-07-31.
What is the analyst price target for Lantheus Holdings?
The mean Wall Street price target for Lantheus Holdings is $106.99 across 8 analysts, 6.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Medical supplies. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.